Juno Therapeutics (JUNO) : Investors lapped up stocks on upticks to the tune of $21.95 million in the Wednesdays trading session. The trading value on downticks was comparatively at $17.97 million and the uptick to downtick ratio of 1.22 indicates continuous buying by the bulls. The net money flow into the stock was $3.98 million. The block trades were dominated by the bulls with a healthy 2, uptick to downtick ratio. Only $2.77 million worth of trades exchanged hands on downticks showing the reluctance of the large traders to part with their holdings. Upticks saw transactions worth $5.54 clearly indicating buying by large investors. The total money flow for block trades stood at $2.77 million, which is a positive for the stock in the long-term. Juno Therapeutics (JUNO) fell $1.95 during the day at $31.48, a drop of -5.82% over the previous days close. However, for the week, the stock is 4.53%, compared to the previous week.
Juno Therapeutics Inc. has lost 0.06% in the last five trading days and dropped 1.6% in the last 4 weeks. Juno Therapeutics Inc. has dropped 20.9% during the last 3-month period . Year-to-Date the stock performance stands at -28.82%.
Juno Therapeutics (JUNO) has an average broker rating of 1.63, which is interpreted as a Buy, as rated by 8 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Juno Therapeutics (NASDAQ:JUNO): stock was range-bound between the intraday low of $30.77 and the intraday high of $33.6108 after having opened at $33.59 on Wednesdays session. The stock finally closed in the red at $33.59, a loss of -6.34%. The stock remained in the red for the whole trading day. The total traded volume was 2,611,629 shares. The stock failed to cross $33.6108 in Wednesdays trading. The stocks closing price on Thursday was $33.42.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.